Skip to main content Accessibility help
×
Home

Treatment with Saccharomyces boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice

  • Priscilla F. C. Justino (a1), Luis F. M. Melo (a1), Andre F. Nogueira (a1), Jose V. G. Costa (a1), Luara M. N. Silva (a1), Cecila M. Santos (a1), Walber O. Mendes (a1), Marina R. Costa (a1), Alvaro X. Franco (a1), Aldo A. Lima (a1), Ronaldo A. Ribeiro (a1), Marcellus H. L. P. Souza (a1) and Pedro M. G. Soares (a1) (a2)...

Abstract

Intestinal mucositis is an important toxic side effect of 5-fluorouracil (5-FU) treatment. Saccharomyces boulardii is known to protect from intestinal injury via an effect on the gastrointestinal microbiota. The objective of the present study was to evaluate the effect of S. boulardii on intestinal mucositis induced by 5-FU in a murine model. Mice were divided into saline, saline (control)+5-FU or 5-FU+S. boulardii (16 × 109 colony-forming units/kg) treatment groups, and the jejunum and ileum were removed after killing of mice for the evaluation of histopathology, myeloperoxidase (MPO) activity, and non-protein sulfhydryl group (mainly reduced glutathione; GSH), nitrite and cytokine concentrations. To determine gastric emptying, phenol red was administered orally, mice were killed 20 min after administration, and the absorbance of samples collected from the mice was measured by spectrophotometry. Intestinal permeability was measured by the urinary excretion rate of lactulose and mannitol following oral administration. S. boulardii significantly reversed the histopathological changes in intestinal mucositis induced by 5-FU and reduced the inflammatory parameters: neutrophil infiltration (control 1·73 (sem 0·37) ultrastructural MPO (UMPO)/mg, 5-FU 7·37 (sem 1·77) UMPO/mg and 5-FU+S. boulardii 4·15 (sem 0·73) UMPO/mg); nitrite concentration (control 37·00 (sem 2·39) μm, 5-FU 59·04 (sem 11·41) μm and 5-FU+S. boulardii 37·90 (sem 5·78) μm); GSH concentration (control 477·60 (sem 25·25) μg/mg, 5-FU 270·90 (sem 38·50) μg/mg and 5-FU+S. boulardii 514·00 (sem 38·64) μg/mg). Treatment with S. Boulardii significantly reduced the concentrations of TNF-α and IL-1β by 48·92 and 32·21 % in the jejunum and 38·92 and 61·79 % in the ileum. In addition, S. boulardii decreased the concentrations of chemokine (C–X–C motif) ligand 1 by 5-fold in the jejunum and 3-fold in the ileum. Interestingly, S. boulardii reduced the delay in gastric emptying (control 25·21 (sem 2·55) %, 5-FU 54·91 (sem 3·43) % and 5-FU+S. boulardii 31·38 (sem 2·80) %) and induced the recovery of intestinal permeability (lactulose:mannitol ratio: control 0·52 (sem 0·03), 5-FU 1·38 (sem 0·24) and 5-FU+S. boulardii 0·62 (sem 0·03)). In conclusion, S. boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in intestinal mucositis induced by 5-FU.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Treatment with Saccharomyces boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Treatment with Saccharomyces boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Treatment with Saccharomyces boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice
      Available formats
      ×

Copyright

Corresponding author

* Corresponding author: Dr P. M. G. Soares, email pedrogsoares@yahoo.com.br

References

Hide All
1 Fuller, R (1991) Probiotics in human medicine. Gut 32, 439442.
2 Laudanno, O, Vasconcelos, L, Catalana, J, et al. (2006) Anti-inflammatory effect of bioflora probiotic administered orally or subcutaneously with live or dead bacteria. Dig Dis Sci 51, 21802183.
3 Dieleman, LA, Goerres, MS, Arends, A, et al. (2003) Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment. Gut 52, 370376.
4 Jespersen, L (2003) Occurrence and taxonomic characteristics of strains of Saccharomyces cerevisiae predominant in African indigenous fermented foods and beverages. FEMS Yeast Res 3, 191200.
5 Buts, JP & De Keyser, N (2006) Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci 51, 14851492.
6 Buts, JP, Stilmant, C, Bernasconi, P, et al. (2008) Characterization of α,α-trehalase released in the intestinal lumen by the probiotic Saccharomyces boulardii . Scand J Gastroenterol 43, 14891496.
7 Sezer, A, Usta, U & Cicin, I (2009) The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea. Med Oncol 26, 350357.
8 Duncan, M & Grant, G (2003) Oral and intestinal mucositis – causes and possible treatments. Aliment Pharmacol Ther 18, 853874.
9 Longley, DB, Harkin, DP & Johnston, PG (2003) 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3, 330338.
10 Sonis, ST (1998) Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 34, 3943.
11 Baerg, J, Murphy, JJ, Anderson, R, et al. (1999) Neutropenic enteropathy: a 10-year review. J Pediatr Surg 34, 10681071.
12 Keefe, DM, Gibson, RJ & Hauer-Jensen, M (2004) Gastrointestinal mucositis. Semin Oncol Nurs 20, 3847.
13 Soares, PM, Mota, JM, Gomes, AS, et al. (2008) Gastrointestinal dysmotility in 5-fluorouracil-induced intestinal mucositis outlasts inflammatory process resolution. Cancer Chemother Pharmacol 63, 9198.
14 MacPherson, BR & Pfeiffer, CJ (1978) Experimental production of diffuse colitis in rats. Digestion 17, 135150.
15 Bradley, PP, Christensen, RD & Rothstein, G (1982) Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood 60, 618622.
16 Sedlak, J & Lindsay, RH (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 25, 192205.
17 Chen, SM, Swilley, S, Bell, R, et al. (2000) Lead induced alterations in nitrite and nitrate levels in different regions of the rat brain. Comp Biochem Physiol C Toxicol Pharmacol 125, 315323.
18 Reynell, PC & Spray, GH (1958) Chemical gastroenteritis in the rat. Gastroenterology 34, 867873.
19 Lima, AA, Silva, TM, Gifoni, AM, et al. (1997) Mucosal injury and disruption of intestinal barrier function in HIV-infected individuals with and without diarrhea and cryptosporidiosis in northeast Brazil. Am J Gastroenterol 92, 18611866.
20 Pearson, AD, Eastham, EJ, Laker, MF, et al. (1982) Intestinal permeability in children with Crohn's disease and coeliac disease. Br Med J (Clin Res Ed) 285, 2021.
21 Deitch, EA (1990) Intestinal permeability is increased in burn patients shortly after injury. Surgery 107, 411416.
22 Sonis, ST, Elting, LS, Keefe, D, et al. (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100, 19952025.
23 Rubenstein, EB, Peterson, DE, Schubert, M, et al. (2004) Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer 100, 20262046.
24 Edens, HA, Levi, BP, Jaye, DL, et al. (2002) Neutrophil transepithelial migration: evidence for sequential, contact-dependent signaling events and enhanced paracellular permeability independent of transjunctional migration. J Immunol 169, 476486.
25 Lima, V, Brito, GA, Cunha, FQ, et al. (2005) Effects of the tumour necrosis factor-α inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters. Eur J Oral Sci 113, 210217.
26 Carneiro-Filho, BA, Oria, RB, Wood Rea, K, et al. (2004) Alanyl-glutamine hastens morphologic recovery from 5-fluorouracil-induced mucositis in mice. Nutrition 20, 934941.
27 Petschow, BW, Carter, DL & Hutton, GD (1993) Influence of orally administered epidermal growth factor on normal and damaged intestinal mucosa in rats. J Pediatr Gastroenterol Nutr 17, 4958.
28 Orazi, A, Du, X, Yang, Z, et al. (1996) Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab Invest 75, 3342.
29 Prisciandaro, LD, Geier, MS, Butler, RN, et al. (2011) Probiotic factors partially improve parameters of 5-fluorouracil-induced intestinal mucositis in rats. Cancer Biol Ther 11, 671677.
30 Smith, CL, Geier, MS, Yazbeck, R, et al. (2008) Lactobacillus fermentum BR11 and fructo-oligosaccharide partially reduce jejunal inflammation in a model of intestinal mucositis in rats. Nutr Cancer 60, 757767.
31 Girard, P, Coppe, MC, Pansart, Y, et al. (2010) Gastroprotective effect of Saccharomyces boulardii in a rat model of ibuprofen-induced gastric ulcer. Pharmacology 85, 188193.
32 Wu, X, Vallance, BA, Boyer, L, et al. (2008) Saccharomyces boulardii ameliorates Citrobacter rodentium-induced colitis through actions on bacterial virulence factors. Am J Physiol Gastrointest Liver Physiol 294, G295G306.
33 Canonici, A, Siret, C, Pellegrino, E, et al. (2011) Saccharomyces boulardii improves intestinal cell restitution through activation of the α2β1 integrin collagen receptor. PLoS ONE 6, e18427.
34 Melo, ML, Brito, GA, Soares, RC, et al. (2008) Role of cytokines (TNF-α, IL-1β and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide. Cancer Chemother Pharmacol 61, 775784.
35 Soares, PM, Lima-Junior, RC, Mota, JM, et al. (2010) Role of platelet-activating factor in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. Cancer Chemother Pharmacol 68, 713720.
36 Fidan, I, Kalkanci, A, Yesilyurt, E, et al. (2009) Effects of Saccharomyces boulardii on cytokine secretion from intraepithelial lymphocytes infected by Escherichia coli and Candida albicans . Mycoses 52, 2934.
37 Lee, SK, Kim, YW, Chi, SG, et al. (2009) The effect of Saccharomyces boulardii on human colon cells and inflammation in rats with trinitrobenzene sulfonic acid-induced colitis. Dig Dis Sci 54, 255263.
38 Wu, ZQ, Han, XD, Wang, Y, et al. (2011) Interleukin-1 receptor antagonist reduced apoptosis and attenuated intestinal mucositis in a 5-fluorouracil chemotherapy model in mice. Cancer Chemother Pharmacol 68, 8796.
39 Yasuda, M, Kato, S, Yamanaka, N, et al. (2012) Potential role of the NADPH oxidase NOX1 in the pathogenesis of 5-fluorouracil-induced intestinal mucositis in mice. Am J Physiol Gastrointest Liver Physiol 302, G1133G1142.
40 Sonis, ST (2004) The pathobiology of mucositis. Nat Rev Cancer 4, 277284.
41 Riezzo, G, Clemente, C, Leo, S, et al. (2005) The role of electrogastrography and gastrointestinal hormones in chemotherapy-related dyspeptic symptoms. J Gastroenterol 40, 11071115.
42 Hollander, D (1999) Intestinal permeability, leaky gut, and intestinal disorders. Curr Gastroenterol Rep 1, 410416.
43 van Vliet, MJ, Harmsen, HJ, de Bont, ES, et al. (2010) The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog 6, e1000879.
44 Wardill, HR & Bowen, JM (2013) Chemotherapy-induced mucosal barrier dysfunction: an updated review on the role of intestinal tight junctions. Curr Opin Support Palliat Care 7, 155161.
45 Garcia Vilela, E, De Lourdes De Abreu Ferrari, M, Oswaldo Da Gama Torres, H, et al. (2008) Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol 43, 842848.
46 Massi, M, Ioan, P, Budriesi, R, et al. (2006) Effects of probiotic bacteria on gastrointestinal motility in guinea-pig isolated tissue. World J Gastroenterol 12, 59875994.
47 Czerucka, D & Rampal, P (2002) Experimental effects of Saccharomyces boulardii on diarrheal pathogens. Microbes Infect 4, 733739.
48 Budriesi, R, Ioan, P, Micucci, M, et al. (2010) Stop Fitan: antispasmodic effect of natural extract of chestnut wood in guinea pig ileum and proximal colon smooth muscle. J Med Food 13, 11041110.
49 McFarland, LV (2010) Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol 16, 22022222.
50 Rodrigues, AC, Nardi, RM, Bambirra, EA, et al. (1996) Effect of Saccharomyces boulardii against experimental oral infection with Salmonella typhimurium and Shigella flexneri in conventional and gnotobiotic mice. J Appl Bacteriol 81, 251256.
51 Czerucka, D, Dahan, S, Mograbi, B, et al. (2001) Implication of mitogen-activated protein kinases in T84 cell responses to enteropathogenic Escherichia coli infection. Infect Immun 69, 12981305.
52 Brandao, RL, Castro, IM, Bambirra, EA, et al. (1998) Intracellular signal triggered by cholera toxin in Saccharomyces boulardii and Saccharomyces cerevisiae . Appl Environ Microbiol 64, 564568.

Keywords

Treatment with Saccharomyces boulardii reduces the inflammation and dysfunction of the gastrointestinal tract in 5-fluorouracil-induced intestinal mucositis in mice

  • Priscilla F. C. Justino (a1), Luis F. M. Melo (a1), Andre F. Nogueira (a1), Jose V. G. Costa (a1), Luara M. N. Silva (a1), Cecila M. Santos (a1), Walber O. Mendes (a1), Marina R. Costa (a1), Alvaro X. Franco (a1), Aldo A. Lima (a1), Ronaldo A. Ribeiro (a1), Marcellus H. L. P. Souza (a1) and Pedro M. G. Soares (a1) (a2)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed